Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : For crawled time : 05:00 save search
Teck Reports Unaudited First Quarter Results for 2024
Published: 2024-04-25 (Crawled : 05:00) - globenewswire.com
TCKRF | $45.95 -7.73% 510
|
Non-Energy Minerals
| Email alert
Add to watchlist
NISTF | News | $22.9 -9.54% 660
|
Non-Energy Minerals
| Email alert
Add to watchlist
PKX | News | $71.38 -0.14% 0.0% 150K
|
Non-Energy Minerals
| Email alert
Add to watchlist
NPSCY | News | $7.6 -1.2% 41K
|
Manufacturing
| Email alert
Add to watchlist
TECK | $45.44 -0.2% 0.0% 3.6M
|
Non-Energy Minerals
| Email alert
Add to watchlist
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
first for results
Banle Group Highlights Strategies for Sustainable Growth During Investor Webinar
Published: 2024-04-25 (Crawled : 05:00) - globenewswire.com
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
| Email alert
Add to watchlist
BANL | $1.0998 -0.95% 12K
|
| Email alert
Add to watchlist
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
| Email alert
Add to watchlist
group for growth
Equinor ASA: Key information relating to cash dividend for first quarter 2024
Published: 2024-04-25 (Crawled : 05:00) - globenewswire.com
EQNR | News | $27.1 -0.07% 0.19% 3.2M
|
Energy Minerals
| Email alert
Add to watchlist
STOHF | News | $28.0 -3.74% 340
|
Energy Minerals
| Email alert
Add to watchlist
first for key
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.36%
H: 0.05%
C: -0.15%
malaria positive treatment for novartis
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Published: 2024-04-23 (Crawled : 05:00) - prnewswire.com
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 1.62%
H: 0.71%
C: 0.23%
cell for collaboration therapeutics diabetes agreement
Renault Group: 2024 Q1 Group revenue at €11.7 billion, +5.9% at constant exchange rate; in the starting-blocks for the upcoming product offensive
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
revenue group for
23andMe, Innate Pharma Tap Antibodies to Target NK Cells for Cancer
Published: 2024-04-22 (Crawled : 05:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: 0.0%
pharma cancer for
Bright Scholar Schedules Unaudited Financial Results for the Second Quarter of Fiscal 2024 Ended February 29, 2024
Published: 2024-04-18 (Crawled : 05:00) - prnewswire.com
BEDU | $1.9 -7.77% 0.0% 6.1K
|
Commercial Services
| Email alert
Add to watchlist
for financial results
Nokia Corporation Interim Report for Q1 2024
Published: 2024-04-18 (Crawled : 05:00) - globenewswire.com
NOK | News | $3.65 -0.82% 0.55% 13M
|
Electronic Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
report corporation for
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Published: 2024-04-17 (Crawled : 05:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
sclerosis for potential
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $375.0 -0.02% -0.02% 200K
|
Health Technology
|
| O: -5.0%
H: 4.19%
C: 2.86%
disease vyvgart for
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
CARBIOS announces fiscal-year 2023 financial results and confirms 2024 calendar for industrial and commercial roll-out
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
PVH 4 | $112.87 0.2% 0.0% 870K
|
Consumer Non-Durables
|
| O: 2.04%
H: 0.19%
C: -1.65%
for commercial financial results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.